Valuation: Labcorp Holdings Inc.

Capitalization 22.38B 19.03B 17.64B 16.49B 30.74B 2,056B 32.58B 202B 80.05B 971B 83.92B 82.2B 3,532B P/E ratio 2025 *
22.8x
P/E ratio 2026 * 19.8x
Enterprise value 27.2B 23.14B 21.45B 20.04B 37.36B 2,499B 39.6B 245B 97.31B 1,180B 102B 99.92B 4,293B EV / Sales 2025 *
1.94x
EV / Sales 2026 * 1.82x
Free-Float
99.96%
Yield 2025 *
1.06%
Yield 2026 * 1.08%
More valuation ratios * Estimated data
Dynamic Chart
01-14 Flywire Corporation Shifts Chief Technology Officer, David King into A New Role of Chief Product Officer & Co-President of Global Education on January 13, 2026 CI
01-14 Baird Adjusts Labcorp Price Target to $313 From $307, Maintains Outperform Rating MT
01-14 Labcorp Holdings Inc. Declares Quarterly Dividend, Payable on March 12, 2026 CI
01-14 Labcorp Holdings Maintains Quarterly Dividend of $0.72 a Share, Payable March 12 to Shareholders of Record as of Feb. 27 MT
01-14 Labcorp Holdings Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 04:30 PM
01-13 Labcorp Adds Recurrence Risk Tests for Breast, Lung, Colon Cancer to MRD Portfolio MT
01-13 Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk CI
01-08 Labcorp's Early Development Medical Device Testing Unit Acquired by NAMSA MT
01-08 Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs CI
01-08 Visby engages Quest and Labcorp to broaden consumer access to first at-home, FDA-authorized PCR test for STIs RE
01-08 Namsa announces strategic acquisition of select assets of the early development medical device testing business of Labcorp RE
01-07 North American Science Associates, LLC acquired Early Development Medical Device Testing Business of Labcorp Holdings Inc. (NYSE:LH). CI
12-15 Labcorp Holdings Inc. Announces Retirement of Mark Schroeder as Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer, Effective April 1, 2026 CI
More news
1 day-1.25%
1 week-1.66%
Current month+6.18%
1 month+5.23%
3 months-6.20%
6 months+6.34%
Current year+6.18%
More quotes
1 week 264.8
Extreme 264.795
275.37
1 month 245
Extreme 245
275.37
Current year 245
Extreme 245
275.37
1 year 209.38
Extreme 209.375
293.72
3 years 191.97
Extreme 191.97
293.72
5 years 191.97
Extreme 191.97
317.17
10 years 97.79
Extreme 97.79
317.17
More quotes
Change 5d. change 1-year change 3-years change Capi.($)
-1.38%-1.66%+9.03%+3.32% 22.38B
+0.66%+0.01%+44.26%+77.92% 106B
+0.54%+5.89%+54.64%-4.55% 105B
-0.21%-2.93%+31.44%+71.83% 32.08B
+1.52%+3.01%-7.55%+18.67% 24.92B
-0.41%-4.31%+19.41%+23.35% 20.26B
+1.06%+8.94%+58.36%+54.67% 18.09B
-0.52%-3.94%+36.65%+266.95% 16.65B
+0.15%+3.67%+9.12%+39.62% 12.85B
-0.72%-0.67%-20.15%+9.83% 12.31B
Average +0.05%-0.13%+23.52%+56.16% 37.09B
Weighted average by Cap. +0.32%-0.61%+36.12%+46.36%
See all sector performances

Financials

2025 *2026 *
Net sales 13.99B 11.9B 11.03B 10.31B 19.22B 1,286B 20.37B 126B 50.05B 607B 52.47B 51.4B 2,208B 14.62B 12.44B 11.53B 10.77B 20.08B 1,344B 21.29B 132B 52.31B 634B 54.83B 53.71B 2,308B
Net income 939M 799M 741M 692M 1.29B 86.3B 1.37B 8.46B 3.36B 40.75B 3.52B 3.45B 148B 1.08B 920M 853M 797M 1.49B 99.37B 1.57B 9.74B 3.87B 46.92B 4.06B 3.97B 171B
Net Debt 4.82B 4.1B 3.8B 3.55B 6.62B 443B 7.02B 43.46B 17.25B 209B 18.09B 17.72B 761B 4.22B 3.59B 3.32B 3.11B 5.79B 387B 6.14B 37.98B 15.08B 183B 15.81B 15.48B 665B
More financial data * Estimated data
Logo Labcorp Holdings Inc.
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and advanced science to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is also focused on clinical diagnostics and reproductive and women's health in the United States outside of New York and New Jersey.
Employees
65,450
More about the company
Date Price Change Volume
23/01/26 266.44 $ -1.31% 223,866
22/01/26 269.97 $ +0.31% 735,309
21/01/26 269.14 $ -0.80% 826,364
20/01/26 271.31 $ +0.16% 1,198,919
16/01/26 270.87 $ +0.74% 1,060,576

Delayed Quote Nyse, January 23, 2026 at 08:14 pm

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
269.97USD
Average target price
300.06USD
Spread / Average Target
+11.15%
Consensus

Quarterly revenue - Rate of surprise